# Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment.

- **DOI:** [10.1007/s12016-025-09027-4](https://doi.org/10.1007/s12016-025-09027-4)
- **Rating:** Sound (3.5 out of 5)
- **Verdict:** An actionable international consensus updates HAE-nC1INH diagnosis and treatment, but uncontrolled and uneven evidence limits confidence in subtype-specific recommendations.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-09-22
- **Evaluation page:** https://www.nabu.science/paper/10.1007%2Fs12016-025-09027-4

## Key claims

1. HAE-nC1INH patients are at risk of serious morbidity and mortality.
   - Support: Supported
   - Type: Primary finding
   - Basis: clinical reports support serious airway risk, although the evidence base is observational and subtype-specific
   - Location: Abstract
2. Plasma-derived C1INH and icatibant are both broadly used and effective ODTs in HAE-XII, HAE-PLG, and HAE-UNK.
   - Support: Tentative
   - Type: Secondary
   - Basis: uncontrolled expert ratings and heterogeneous subtype samples limit efficacy inference
   - Location: Section 3, Further Real-World Studies and Clinical Trials
3. LTP with progestin may be considered for HAE-FXII patients.
   - Support: Tentative
   - Type: Secondary
   - Basis: the recommendation rests on case series and uncontrolled survey ratings from a small sample
   - Location: Section 3, Further Real-World Studies and Clinical Trials
4. Even without an identified mutation, a presumptive diagnosis of HAE-nC1INH made by an expert physician is sufficient.
   - Support: Tentative
   - Type: Secondary
   - Basis: expert consensus supports the recommendation amid absent validated biomarkers and continuing diagnostic uncertainty
   - Location: Conclusion and Forward-Looking Statement
5. Lanadelumab may be considered as an option for LTP in HAE-FXII and HAE-UNK, and it may help some patients with HAE-PLG.
   - Support: Tentative
   - Type: Secondary
   - Basis: small uncontrolled samples include mixed responses and worsening in HAE-PLG
   - Location: Section 3, Further Real-World Studies and Clinical Trials

## Strengths

- **Operational eight-step diagnostic pathway** Figure 1 and the accompanying numbered steps turn a complex differential diagnosis into a clinical sequence covering documentation, C1INH testing, medication causes, mast-cell therapy, genetics, treatment response, and family screening.
  - Dimension: methodological rigour
  - Location: Section 1, Figure 1 and Diagnostic Algorithm Steps 1–8
- **Substantive international treatment dataset** The HCT survey aggregates expert-reported outcomes for 594 patients from 15 countries, adding subtype-specific treatment information to a sparse literature.
  - Dimension: contribution
  - Location: Section 3, HCT survey; Figures 2–4
- **Evidence limitations shape recommendations** The paper withholds recommendations where short-term prophylaxis evidence is insufficient and declines to recommend attenuated androgens because benefit is inconsistent and harms are known.
  - Dimension: positioning
  - Location: Section 3, Further Real-World Studies and Clinical Trials

## Limitations

- **Literature selection method remains undescribed** The Introduction explains the symposium and revision process but not how studies were searched for, selected, or evaluated, limiting assessment of completeness and balance.
  - Dimension: methodological rigour
  - Location: Introduction
- **Subtype samples are highly uneven** Treatment conclusions range from substantial HAE-FXII and HAE-UNK groups to one- or two-patient observations and no reported outcomes for some subtypes, sharply limiting generalization.
  - Dimension: application pathway
  - Location: Section 3, HCT survey; Figures 2–4
- **Survey precision exceeds evidentiary stability** Exact efficacy percentages are sometimes calculated from very small, expert-rated samples, while the survey instrument and detailed administration methods are deferred to an unavailable supplement.
  - Dimension: positioning
  - Location: Section 3, HCT survey and Figures 2–4

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The article is internally consistent overall, but precise treatment-response percentages may convey more stability than very small subtype denominators support. No statistical impossibility or contradiction was identified.
- **Research conduct:** Noted. No demonstrated distortion or other substantive conduct problem appears in the supplied text. A conflict-of-interest disclosure is absent despite organisational sponsorship and extensive discussion of commercial therapies; detailed survey materials in the unavailable supplement remain an assessability gap.
- **Reference integrity:** Clean. 140 of 140 checkable references verified
  - 140 references in manuscript
  - citation details diverge from the cited records for 1 reference
  - Citation details diverge for 1 reference:
    - #126 Veronez CL, Campos RA, Constantino-Silva RN, Nicolicht P, Pesquero JB, Grumach AS (2019) Hereditary angioedema-associated acute pancreatitis in C1-inhibitor deficient and normal C1-inhibitor patients: case reports and literature review. Front Med (Lausanne) 6:80. 10.3389/fmed.2019.00080 31058156 PMC6478673 (Differs from the cited DOI’s record on: container, authors)
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
